• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Novavax Inc. (Amendment)

    4/15/24 12:18:22 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVAX alert in real time by email
    SC 13D/A 1 fp0087987-2_sc13da.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _____________

     

    SCHEDULE 13D/A

    (Amendment No. 1) 

     

    Under the Securities Exchange Act of 1934

     

     

    NOVAVAX, INC.

    (Name of Issuer)

     

    Common Stock, Par Value $0.01 per share

    (Title of Class of Securities)

     

    670002401

    (CUSIP Number)

     

    Shah Capital Management, Inc.

    2301 Sugar Bush Road, Suite 510

    Raleigh, NC 27612

    (919) 719-6360

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

     

    April 10, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D and is filing this schedule because of §§ 240.13d-1(e), 240-13d.1(f) or 240.13d-1(g), check the following box: [X]

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    *       The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

     

     


    CUSIP NO. 670002401
    13D Page 2 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Shah Capital Management

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [    ]

    (b) [    ]

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (Other)

     

    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) [ ]
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of North Carolina, United States of America

     

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING
    PERSON
    WITH

    7

    SOLE VOTING POWER

     

    N/A

    8

    SHARED VOTING POWER

     

    9,326,176 shares

    9

    SOLE DISPOSITIVE POWER

     

    N/A

    10

    SHARED DISPOSITIVE POWER

     

    9,326,176 shares

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,326,176 shares

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES

    CERTAIN SHARES

    [    ]             

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    6.66% of the outstanding shares

    12

    TYPE OF REPORTING PERSON

     

    IA (Investment Adviser)

     

     

     

     


    CUSIP NO. 670002401
    13D Page 3 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Shah Capital Opportunity Fund LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [    ]

    (b) [    ]

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (Other)

     

    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) [ ]
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

     

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING
    PERSON
    WITH

    7

    SOLE VOTING POWER

     

    N/A

    8

    SHARED VOTING POWER

     

    8,700,000 shares

    9

    SOLE DISPOSITIVE POWER

     

    N/A

    10

    SHARED DISPOSITIVE POWER

     

    8,700,000 shares

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,700,000 shares

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES

    CERTAIN SHARES

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    6.21% of the outstanding shares

    12

    TYPE OF REPORTING PERSON

     

    PN (Partnership)

    [    ]            

     

     

     


    CUSIP NO. 670002401
    13D Page 4 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Himanshu H. Shah

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [    ]

    (b) [    ]

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    PF (Personal Funds)

     

    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) [ ]
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING PERSON WITH

    7

    SOLE VOTING POWER

     

    57,159 shares

    8

    SHARED VOTING POWER

     

    9,326,176 shares

    9

    SOLE DISPOSITIVE POWER

     

    57,159 shares

    10

    SHARED DISPOSITIVE POWER

     

    9,326,176 shares

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,383,335 shares

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES

    CERTAIN SHARES

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    6.70% of the outstanding shares

    12

    TYPE OF REPORTING PERSON

     

    IN (Individual)

    [    ]            

     

     

     

     


    CUSIP NO. 670002401
    13D Page 5 of 15 Pages

     

    Item 1. Security and Issuer.

     

    (a)Name of Issuer:

    NOVAVAX, INC.

     

    (b)Address of Issuer's Principal Executive Offices

    700 Quince Orchard Road

    Gaithersburg, Maryland 20878

     

    Item 2. Identity and Background.

     

    (a)Name.

     

    This Statement is filed by:

     

    (i)Shah Capital Management, Inc. ("Shah Capital"), a North Carolina corporation, who serves as the investment adviser to Shah Opportunity (as defined below);

     

    (ii)Shah Capital Opportunity Fund LP ("Shah Opportunity"), a Delaware limited partnership; and

     

    (iii)Himanshu H. Shah, who serves as President and Chief Investment Officer of Shah Capital.

     

    Shah Capital, Shah Opportunity and Mr. Shah are referred to collectively as the "Reporting Persons."

     

    (b)Residence of Business Address

     

    The address of the principal business and principal office of each of the Reporting Persons is 2301 Sugar Bush Road, Suite 510, Raleigh, North Carolina 27612.

     

    (c)Present Principal Occupation or Employment and the Name, Principal Business and Address of any Corporation or Other Organization in Which Such Employment Is Conducted

     

    The principal business of each of Shah Capital and Shah Opportunity is investing in securities.

     

    The principal occupation of Mr. Shah is serving as the President and Chief Investment Officer of Shah Capital.

     

    (d)Criminal Convictions

     

    During the past five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)Civil Proceedings

     

    During the past five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding such person was or is

     

     

     

     


    CUSIP NO. 670002401
    13D Page 6 of 15 Pages

     

    subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)Citizenship

     

    Shah Capital is a North Carolina corporation.

    Shah Opportunity is a Delaware limited partnership.

    Mr. Shah is a citizen of the United State of America.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Except for 57,159 shares owned directly by Mr. Shah, which were purchased using his personal funds, all of the shares to which this Statement relates were purchased on behalf of the Reporting Persons using the investment capital of the Reporting Persons. All shares were purchased in various transactions and for various amounts of consideration through open market purchases.

     

    Item 4. Purpose of Transaction

     

    The Reporting Persons purchased the shares for investment purposes, and such purchases have been made in the ordinary course of business of the Reporting Persons.

     

    The Reporting Persons do not have any present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. In pursuing investment purposes, the Reporting Persons may further purchase, hold, vote, trade, dispose or otherwise deal in the shares at times, and in such manner, as they deem advisable to benefit from, among other things: (1) changes in the market prices of the shares; (2) changes in the Issuer's operations, business strategy or prospects; or (3) from the sale, merger, or other proposed corporation transaction pursued or closed with respect to the Issuer or a third party. To evaluate such alternatives, the Reporting Persons will monitor the Issuer's operations, business, management, capital structure, financials, and prospects; competitive and strategic matters related to the Issuer's business, competitors' businesses, and the industry generally; corporate transactions and potential corporate transactions involving the Issuer; and prevailing market conditions, as well as other economic, securities markets and investment considerations. Consistent with their investment research methods and evaluation criteria, the Reporting Persons has discussed, engaged with and may continue to discuss such matters with the Issuer's management or the Board of Directors, other stockholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit, and other investors. Such evaluations and discussions may materially affect, and result in, among other things, the Reporting Persons: (1) modifying their ownership of the shares, including, without limitation, the purchase or sale of shares in the open market or through privately negotiated transactions of otherwise; (2) exchanging information with the Issuer pursuant to appropriate confidentiality or similar agreements; (3) proposing changes in the Issuer's operations, governance or capitalization; or (4) pursuing one or more of the other actions described in subsections (a) through (j) of Item 4 of §240.13d-101. The Reporting Persons may at any time reconsider and change their plans or proposals relating to the foregoing.

     

     

     

     

     


    CUSIP NO. 670002401
    13D Page 7 of 15 Pages

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 (a) and (b)

     

     

    Shah Capital
    Management

     Shah Capital
    Opportunity Fund
    LP 

     Himanshu H. Shah

    (a) Amount Beneficially Owned: 9,326,176 8,700,000 9,383,335
    (b) Percent of Class:* 6.66% 6.21% 6.70%

    (c)

    Number of Shares to Which Reporting Person Has:

     
      (i) Sole Voting Power: N/A N/A 57,159
      (ii) Shared Voting Power: 9,326,176 8,700,000 9,326,176
      (iii) Sole Dispositive Power: N/A N/A 57,159
      (iv) Shared Dispositive Power: 9,326,176 8,700,000 9,326,176

     

    The percentage in this paragraph relating to beneficial ownership of shares is based on 140,000,000 shares outstanding as of February 29, 2024.

     

    (c) Except as disclosed below, none of the Reporting Persons have effected any transactions in the shares of Common Stock in the 60 days prior to the date of this Statement.

     

    1,550,000 shares bought at total cost of $7,075,378 (inclusive of commission)

     

    (d) No other person is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of no par value covered by this Statement.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Other than as described in this Statement, to the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any other persons with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

     

     

     


    CUSIP NO. 670002401
    13D Page 8 of 15 Pages

     

    Item 7. Material to be Filed as Exhibits.

     

    The following documents are filed as exhibits:

     

    Exhibit Number Description
    Exhibit 99.1 Joint Filing Agreement, dated April 15, 2024, by and among Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah.
    Exhibit 99.2 BOD Letter

     

     

     

    Signature

     

    After reasonable inquiry and to the best of each of the undersigned's knowledge and belief, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

      Date: April 15, 2024  
         
     

    SHAH CAPITAL MANAGEMENT, INC.

     
         

    By:

    /s/ Himanshu H. Shah 

     
     

    Name:

    Himanshu H. Shah

     
      Title: President and Chief Investment Officer  
         
      Date: April 15, 2024  
         
     

    SHAH CAPITAL OPPORTUNITY FUND LP

     
         
     

    By:

    /s/ Himanshu H. Shah

     
     

    Name:

    Himanshu H. Shah

     
      Title: Managing Member  
         
      Date: April 15, 2024  
         
     

    /s/ Himanshu H. Shah

     
      Himanshu H. Shah  
         

     

    Get the next $NVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVAX

    DatePrice TargetRatingAnalyst
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    8/9/2023$15.00Neutral → Buy
    B. Riley Securities
    4/20/2023$55.00 → $10.00Outperform → Market Perform
    TD Cowen
    3/1/2023$29.00 → $10.00Buy → Neutral
    B. Riley Securities
    1/9/2023$74.00 → $37.00Buy
    B. Riley Securities
    More analyst ratings

    $NVAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

      FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

      5/8/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Participate in BofA Securities 2025 Health Care Conference

      GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 14, 2025 Time: 3:00 – 3:30 p.m. Pacific Time (PT) Location: Las Vegas, NV Conference Event: Investor Meetings Date: Wednesday, May 14, 2025 A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines

      5/7/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

      Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will continue to be available in Japan, the world's third largest pharmaceutical marketGAITHERSBURG, Md., May 5, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regu

      5/5/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Novavax with a new price target

      BTIG Research initiated coverage of Novavax with a rating of Buy and set a new price target of $19.00

      2/28/25 7:28:04 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax downgraded by JP Morgan with a new price target

      JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00

      7/30/24 6:25:22 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax upgraded by BofA Securities with a new price target

      BofA Securities upgraded Novavax from Underperform to Neutral and set a new price target of $12.00 from $4.00 previously

      5/10/24 1:12:36 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Leadership Updates

    Live Leadership Updates

    See more
    • Novavax Appoints Charles Newton to Board of Directors

      GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

      4/29/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

      Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

      1/23/25 9:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

      Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organizationDr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platformGAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D). Dr. Draghia-Akli brings m

      9/25/24 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Financials

    Live finance-specific insights

    See more
    • Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

      FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

      5/8/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

      GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/43UHjFq Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants

      5/1/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohortCompleted $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 millionAdvanced pipeline programs, based on proven and innovative technology platformEnded full year 2024 with over $1 billion in Cash and accounts receivablesProvides 2025 financial guidance and revenue framew

      2/27/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

      For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

      9/3/24 2:26:49 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

      For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

      8/30/24 2:26:48 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

      For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

      10/3/23 2:56:27 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $NVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Newton Charles W.

      4 - NOVAVAX INC (0001000694) (Issuer)

      4/29/25 8:08:08 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Newton Charles W.

      3 - NOVAVAX INC (0001000694) (Issuer)

      4/29/25 8:06:39 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shiver John W.

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/12/25 8:04:38 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    SEC Filings

    See more
    • Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NOVAVAX INC (0001000694) (Filer)

      5/8/25 8:26:56 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Novavax Inc.

      10-Q - NOVAVAX INC (0001000694) (Filer)

      5/8/25 7:59:11 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - NOVAVAX INC (0001000694) (Filer)

      5/5/25 9:25:23 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      11/12/24 4:46:17 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      11/4/24 1:19:04 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      7/10/24 6:16:55 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care